SCHEMBL17670548

SCHEMBL17670548

Fc1cc(Br)cc(F)c1Cc1cccnc1

nearest known ligand 0.46

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CYP2A6 P11509 1/20 0.46
CHRNA7 P36544 1/20 0.44
MEN1 O00255 2/20 0.44
KMT2A Q03164 2/20 0.44
MAPT P10636 1/20 0.44
PABPC1 P11940 1/20 0.44
HRH4 Q9H3N8 1/20 0.42
HRH3 Q9Y5N1 1/20 0.42
CYP1A2 P05177 1/20 0.42
CYP2D6 P10635 1/20 0.42
MMP2 P08253 1/20 0.41
HRH1 P35367 2/20 0.40
PTGDR2 Q9Y5Y4 1/20 0.40
GAA P10253 1/20 0.40
CHRNB2 P17787 2/20 0.40
CHRNA4 P43681 2/20 0.40
CYP11B1 P15538 1/20 0.40
CYP11B2 P19099 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8307942 0.79 CYP11B1 (0.47) CHRNA7HRH4HRH3CYP1A2CYP2D6
SCHEMBL727185 0.73 CYP1A2 (0.62) CYP2A6CHRNA7HRH4HRH3CYP1A2
SCHEMBL1773262 0.73 TBXAS1 (0.56) CHRNA7MEN1KMT2AHRH4HRH3
SCHEMBL17922967 0.72 MEN1 (0.45) MEN1KMT2AMAPTHRH4HRH3
SCHEMBL14257669 0.72 CYP1A2 (0.56) CYP2A6CHRNA7HRH4HRH3CYP1A2
SCHEMBL10487080 0.72 NTRK1 (0.54) CHRNA7MEN1KMT2AMAPTPABPC1
SCHEMBL30861994 0.70 PKM (0.51) CHRNA7KMT2AHRH4HRH3CYP1A2
SCHEMBL10487072 0.70 PKM (0.51) CHRNA7KMT2AHRH4HRH3CYP1A2
SCHEMBL22172497 0.69 CHRNB2 (0.50) CHRNA7HRH4HRH3CYP1A2CYP2D6
SCHEMBL3758352 0.69 TBXAS1 (0.56) HRH4HRH3CYP1A2CYP2D6GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160102090-A1 SUBSTITUTED 3-BENZYLQUINOXALIN-4(3H)-ONE ANALOGS AS POSITIVE ALLOSTERIC MODULATORS OF MUSCARINIC ACETYCHOLINE RECEPTOR M1 VANDERBILT UNIVERSITY (US) 2016-04-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160102090-A1 SUBSTITUTED 3-BENZYLQUINOXALIN-4(3H)-ONE ANALOGS AS POSITIVE ALLOSTERIC MODULATORS OF MUSCARINIC ACETYCHOLINE RECEPTOR M1 CHRM1, CHRM3, CHRM4 CYP2A6 2115/4885CHRNA7 12/4885MEN1 1890/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.